Dr Robert D Holsey, DO | |
100 Main Street, Binger, OK 73009-0482 | |
(405) 656-2306 | |
(405) 656-2265 |
Full Name | Dr Robert D Holsey |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 100 Main Street, Binger, Oklahoma |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972616647 | NPI | - | NPPES |
100118130A | Medicaid | OK |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 2172 (Oklahoma) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Robert D Holsey, DO Po Box 482, Binger, OK 73009-0482 Ph: (405) 656-2306 | Dr Robert D Holsey, DO 100 Main Street, Binger, OK 73009-0482 Ph: (405) 656-2306 |
News Archive
To mark Day of the African Child on Tuesday, the U.N. Millennium Campaign is calling on African governments, civil society organizations and the private sector to address child and maternal mortality and other targets related to the U.N. Millennium Development Goals (MDGs), InDepthNews reports (Mwanda, InDepthNews, 6/16), while Save the Children released a new briefing paper, indicating that more than 1,500 babies born in sub-Saharan Africa die daily, "mostly from preventable or treatable causes," (Save the Children release, 6/16).
Prospects for a safe, effective AIDS vaccine are improving as researchers from the public and private sectors begin to collaborate in new and creative ways, researchers said recently at the 2005 Annual Meeting of the American Association for the Advancement of Science (AAAS).
Practis, Inc., a distinguished healthcare web design firm, and Primetime Medical Software, the leading provider of patient interviewing technology, partnered to deliver Practis Forms—new healthcare software that allows practices to administer medical history and other clinical questionnaires securely through their current website.
Tolerx, Inc., today announced the completion of patient enrollment in its Phase 3 clinical study DEFEND-1, which is evaluating the safety and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with new-onset autoimmune type 1 diabetes.
› Verified 8 days ago